Gene therapy for rare retinal disorder to cost $425,000 per eye

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited ...

Posted: Jan 4, 2018 9:16 AM
Updated: Jan 4, 2018 9:16 AM

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye.

Spark Therapeutics Inc., the Philadelphia-based maker of voretigene neparvovec, announced Wednesday in a statement that it reached an agreement in principle with Harvard Pilgrim and affiliates of-Express Scripts to make the one-time treatment available to patients with a rare genetic defect that often leads to blindness.

Luxturna, a one-time treatment, corrects a genetic mutation that can lead to blindness

Spark Therapeutics set the price for the gene therapy at $425,000 per eye

The mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.

In some cases, the gene therapy will be available under an "outcomes-based rebate arrangement." The company also stated that its proposal to the Centers for Medicare and Medicaid Services, the government program that covers about 100 million Americans, would allow installment payments for the drug.

"For a one-time therapy, like Luxturna, a non-traditional payment and distribution model is necessary to ensure needs of all parties -- patients, payers and providers -- are addressed," said Jennifer Luddy, a spokeswoman for Express Scripts.

At least one patient advocate disagrees.

"The new payment models announced today are merely a way to disguise a price that is simply too high," David Mitchell, president and founder of Patients For Affordable Drugs, said in a statement. "Spark Therapeutics is charging as much for Luxturna as they think they can get away with."

Spark Therapeutics CEO Jeff Marrazzo co-authored a recent blog post in the journal Health Affairs that said "the current payment system -- accustomed to ongoing treatment of chronic diseases -- creates significant challenges" for gene therapies and other treatments.

One-time-only treatments for rare genetic disorders are still unique, he noted.

The drug is intended for patients with retinal dystrophy due to a mutation of the RPE65 gene. This rare genetic defect causes severe visual impairment beginning in infancy and can eventually lead to blindness. The company believes the total "population in the US, Europe and select additional markets in the Americas and Asia/Pacific is up to approximately 6,000 individuals" who have the mutation targeted by Luxturna, explained Monique da Silva, a spokeswoman for Spark Therapeutics.

The drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.

Luxturna is only the third gene therapy approved for use in the United States; two others were also approved in 2017. This is the first to correct an inherited genetic mutation.

Luxturna-is a liquid that is injected directly into the eye with a microscopic needle during a surgical procedure. The drug supplies a third gene -- a normal RPE65 gene -- to cells in the retina, a layer of tissue lining the back of the eye.-This third version of the gene does not remove or replace the two mutated genes causing the disease, which remain inside the cells. However, the normal gene delivered by the treatment is able to function within the retinal cells and correct vision problems.

In the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company. Risks of the treatment include cataracts, elevated eye pressure, retinal tears and holes and inflammation.

The company's offer of unusual payer models, including rebates and installment payments, will "help ensure patients' individual financial situation does not hinder access to treatment," da Silva said.

"New technologies such as gene and cell therapies hold out the potential to transform medicine," FDA Commissioner Dr. Scott Gottlieb-said in a statement announcing the August approval of Kymriah, considered to be the first gene therapy to be approved for the US market.

Kymriah is a leukemia treatment made by pharmaceutical giant Novartis. Similar to Luxturna, Kymriah is a one-time treatment, and its price tag is $475,000. However, Novartis said this price will not be charged to patients who do not respond within a month of treatment.

Indiana Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 36578

Reported Deaths: 2258
CountyConfirmedDeaths
Marion10188604
Lake3876207
Allen181071
Cass15919
Elkhart158528
St. Joseph135838
Hendricks120478
Hamilton119194
Johnson1125113
Madison60061
Porter56233
Clark53942
Bartholomew53139
LaPorte44824
Howard44236
Tippecanoe4344
Jackson4012
Delaware39741
Shelby39722
Hancock35427
Boone32436
Floyd31941
Vanderburgh2913
Morgan28626
Noble27821
Montgomery24917
Clinton2471
White2399
Decatur23132
Grant22923
Dubois2113
Kosciusko2052
Harrison19622
Marshall1872
Henry18512
Vigo1828
Greene17226
Dearborn17122
Monroe17113
Lawrence17124
Warrick16729
Miami1461
Putnam1427
Jennings1324
Orange13122
LaGrange1282
Scott1263
Franklin1168
Ripley1086
Daviess10416
Carroll952
Wayne906
Steuben902
Wabash812
Newton8010
Fayette797
Jasper741
Jay580
Clay533
Randolph523
Rush513
Fulton511
Washington501
Pulaski500
Jefferson491
Whitley453
DeKalb451
Starke423
Perry390
Huntington382
Sullivan371
Wells350
Owen341
Brown331
Benton320
Knox310
Blackford272
Tipton261
Crawford250
Adams231
Switzerland220
Spencer221
Fountain222
Gibson202
Parke180
Posey160
Martin140
Warren131
Ohio130
Vermillion100
Union100
Pike60
Unassigned0180

Ohio Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 37758

Reported Deaths: 2357
CountyConfirmedDeaths
Franklin6323295
Cuyahoga4789265
Hamilton2811171
Marion268832
Lucas2329263
Pickaway209938
Summit1529181
Mahoning1486191
Butler97532
Columbiana89453
Stark803102
Montgomery73417
Lorain73061
Trumbull60052
Belmont44915
Warren40721
Medina37624
Tuscarawas3714
Ashtabula36938
Miami36730
Delaware36014
Portage33557
Lake32512
Clark3237
Fairfield3188
Wood30649
Geauga30334
Wayne29651
Licking27110
Mercer2278
Richland2224
Allen22133
Clermont2195
Darke19023
Erie18416
Madison1647
Washington11819
Crawford1184
Morrow1081
Ottawa10717
Greene1065
Putnam9514
Sandusky9112
Monroe8015
Auglaize773
Hardin730
Ross732
Hocking705
Jefferson672
Huron611
Williams581
Holmes573
Union561
Muskingum561
Hancock531
Coshocton480
Wyandot482
Clinton471
Shelby473
Fulton450
Logan430
Fayette410
Preble391
Guernsey382
Carroll353
Defiance342
Brown311
Lawrence301
Highland291
Champaign281
Seneca262
Knox251
Ashland230
Vinton212
Perry191
Athens181
Scioto180
Henry170
Jackson150
Paulding140
Adams111
Harrison100
Pike90
Gallia81
Van Wert70
Meigs60
Noble60
Morgan50
Unassigned00
Fort Wayne
Scattered Clouds
75° wxIcon
Hi: 88° Lo: 64°
Feels Like: 75°
Angola
Broken Clouds
70° wxIcon
Hi: 86° Lo: 63°
Feels Like: 70°
Huntington
Clear
74° wxIcon
Hi: 87° Lo: 64°
Feels Like: 74°
Decatur
Clear
75° wxIcon
Hi: 87° Lo: 65°
Feels Like: 75°
Van Wert
Clear
75° wxIcon
Hi: 89° Lo: 66°
Feels Like: 75°
Sunny & Pleasant Weekend
WFFT Radar
WFFT Temperatures
WFFT National

Community Events